The Cost And Productivity Consequences Of Non-Severe Hypoglycaemic Episodes (Nshe) In Patients Treated With Sulfonylurea Or Dpp4 Dual Combination Oral Therapy

•Hypoglycaemia is a substantial healthcare burden in terms of resource utilization, costs and quality of life for people with type 2 diabetes [1]. •Non-severe hypoglycaemia episodes (NSHE) occur more frequently than severe episodes and account for the majority of hypoglycaemic burden; recent data has quantified the per-event costs of NSHE in terms of productivity loss and out-of-pocket (OOP) expenses [2]. •The aim of this study was to assess the implications for cost effectiveness (CE) associated with the inclusion of NSHE related indirect costs; illustrated by comparing the CE of sulfonylurea (SU) versus DPP-4 based dual combination blood glucose lowering regimens.